Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$503.00K$503.00Kderived−43.9% vs Q4 2019 Net Income-$280.50M-$280.50MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$23,559,000N/M Operating Cash Flowderived-$10,203,000N/M Margins · derivedOperating margin-4683.7%−3947.5 pt vs Q4 2019
Net margin-55765.2%
ended Dec 31, 2020 · filed Mar 31, 2021 · 90 d after period end